【中国之声，全球视野】ASH 2024专题报道蓄势开启！

文摘 2024-12-06 19:50 上海

第66届美国血液学年会（ASH 2024）将于2024年12月7-10日在美国圣迭戈召开。ASH年会是全球血液学领域大规模全面涵盖恶性与非恶性血液病学的国际盛会，每年都会吸引来自全球100多个国家的25000余名血液学家和其他相关医疗保健专业人士参会。

今年，中国医学论坛报今日血液特别策划“中国之声，全球视野——ASH 2024专题报道”，通过中国医学论坛报融媒体平台展示全球血液学领域的最新研究进展和突破性临床数据，并通过视频连线重磅专家，解析研究成果，指导中国临床实践；前方记者还将与中国知名专家和学者在会议现场进行面对面交流，采写独家报道，第一时间与读者分享。请大家持续关注！

ASH 2024中国专家部分研究成果抢先了解：

JAK/ROCK抑制剂Rovadicitinib用于糖皮质激素耐药或依赖性慢性移植物抗宿主病：多中心Ib/IIa期试验更新结果

摘要号：97

英文标题：JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease: Updated Results of Multicenter, Phase 1b/2a Trial

时间：Saturday, December 7, 2024: 9:30 AM

报告人：Yanmin Zhao

一项Ⅱ期研究，评估Pimicotinib （ABSK021）在1线或多线系统治疗后慢性移植物抗宿主病（cGvHD）中的有效性和安全性

摘要号：99

英文标题：A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

时间：Saturday, December 7, 2024: 10:00 AM

报告人：Depei Wu

多组学分析揭示了类固醇耐药性移植物抗宿主病的免疫特征

摘要号：101

英文标题：Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease

时间：Saturday, December 7, 2024: 10:30 AM

报告人：Zengkai Pan

Tgrx-678（一种强效BCR::ABL1变构抑制剂）在酪氨酸激酶抑制剂耐药和/或不耐受的慢性髓系白血病患者中的安全性和有效性：I期研究Tgrx-678 -1001的更新结果

摘要号：477

英文标题：Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

时间：Sunday, December 8, 2024: 10:00 AM

报告人：Qian Jiang

奥雷巴替尼作为慢性期慢性髓系白血病患者的二线治疗

摘要号：480

英文标题：Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

时间：Sunday, December 8, 2024: 10:45 AM

报告人：Li Weiming

海曲泊帕联合免疫抑制治疗用于重度再生障碍性贫血的一线治疗：一项随机、双盲、安慰剂对照的3期试验

摘要号：304

英文标题：Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

时间：Saturday, December 7, 2024: 4:45 PM

报告人：Fengkui Zhang

双顺反子CD19/CD22 CAR T细胞疗法在儿童B细胞急性淋巴细胞白血病中的安全性和有效性研究

摘要号：681

英文标题：Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

时间：Sunday, December 8, 2024: 5:00 PM

报告人：Hua Zhang

CD19 CAR T细胞疗法在难治性自身免疫性溶血性贫血中的应用

摘要号：682

英文标题：CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia

时间：Sunday, December 8, 2024: 5:15 PM

报告人：Ruonan Li

序贯输注抗CD19和抗BCMA嵌合抗原受体T细胞：一种治疗难治性免疫介导的血小板输注无效的有前景的治疗策略

摘要号：683

英文标题：Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

时间：Sunday, December 8, 2024: 5:30 PM

报告人：Yunju Ma

异基因造血干细胞移植治疗输血依赖性地中海贫血患者的多中心临床试验

摘要号：378

英文标题：A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

时间：Saturday, December 7, 2024: 5:15 PM

报告人：Rongrong Liu

新型Syk抑制剂TQB3473在成人免疫性血小板减少症（ITP）患者中的初步疗效和安全性结果

摘要号：711

英文标题：Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)

时间：Monday, December 9, 2024: 11:00 AM

报告人：Hu Zhou

生物标志物MSC-C5b-9指导的全反式维甲酸治疗难治性/复发性ITP的更新结果：一项多中心、随机、开放标签的3期临床试验

摘要号：712

英文标题：Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

时间：Monday, December 9, 2024: 11:15 AM

报告人：Menglin Li

地西他滨联合全反式维甲酸对比地西他滨单药治疗骨髓增生异常综合征伴原始细胞增多的一项多中心、随机对照试验

摘要号：663

英文标题：Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

时间：Sunday, December 8, 2024: 5:00 PM

报告人：Hongyan Tong

异基因造血干细胞移植后微小剂量贝林妥欧单抗维持治疗在急性B细胞淋巴细胞白血病中的应用

摘要号：1049

英文标题：Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia

时间：Monday, December 9, 2024: 5:30 PM

报告人：Jie Ji

2期临床试验更新结果：阿扎胞苷和西达本胺在高危急性髓系白血病患者异基因造血干细胞移植后维持治疗的安全性和有效性

摘要号：1050

英文标题：Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

时间：Monday, December 9, 2024: 5:45 PM

报告人：Rui Huang

利妥昔单抗、来那度胺和泽布替尼（ZR2）序贯CAR-T细胞作为高危大B细胞淋巴瘤的一线治疗

摘要号：91

英文标题：Rituximab, Lenalidomide, and Zanubrutinib (ZR2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

时间：Saturday, December 7, 2024: 9:30 AM

报告人：Mingming Zhang

表达IL-10的CD19 CAR-T细胞在复发或难治性B细胞血液恶性肿瘤中诱导完全缓解并改善长期保护作用

摘要号：92

英文标题：IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

时间：Saturday, December 7, 2024: 9:45 AM

报告人：Jingjing Ren

一种高选择性和口服生物可利用的CK1α分子胶降解剂靶向B细胞淋巴瘤细胞

摘要号：956

英文标题：A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells

时间：Monday, December 9, 2024: 4:45 PM

报告人：Ran Kong

KPT-330 联合放射治疗：有效降低神经毒性的中枢神经系统淋巴瘤治疗方法

摘要号：958

英文标题：KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

时间：Monday, December 9, 2024: 5:15 PM

报告人：Bingzong Li

CD93+ 髓系细胞抑制 T 细胞介导的抗肿瘤免疫

摘要号：960

英文标题：CD93+ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

时间：Monday, December 9, 2024: 5:45 PM

报告人：Hui Yu

维奈克拉联合HAG方案治疗新诊断ETP-ALL：一项前瞻性、多中心、Ⅱ期试验

摘要号：836

英文标题：Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

时间：Monday, December 9, 2024: 3:00 PM

报告人：Shanshan Suo

Tucidinostat 联合类似于儿童的化疗作为新诊断ETP-ALL/LBL 的一线治疗：一项开放标签、单臂、II期试验

摘要号：839

英文标题：Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

时间：Monday, December 9, 2024: 3:45 PM

报告人：Jieping Lin

泽布替尼联合来那度胺治疗复发/难治性弥漫大B细胞淋巴瘤患者的I期研究最终分析

摘要号：986

英文标题：Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

时间：Monday, December 9, 2024: 4:45 PM

报告人：Zheng Song

Rovadicitinib 治疗噬血细胞性淋巴组织细胞增多症患者：一项单臂、开放标签、I期研究

摘要号：806

英文标题：Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study

时间：Monday, December 9, 2024: 3:00 PM

报告人：Zhao Wang

新型RIPK1抑制剂通过程序性坏死治疗噬血细胞性淋巴组织细胞增多症的药理学和机制研究

摘要号：810

英文标题：Pharmacological and Mechanism Study of a New RIPK1 Inhibitor Via Necroptosis to Treat Hemophagocytic Lymphohistiocytosis

时间：Monday, December 9, 2024: 4:00 PM

报告人：Jinbing Zhu

抗BCMA/GPRC5D双特异性CAR-T细胞治疗针对复发难治性多发性骨髓瘤伴髓外病变患者的一项单中心、单臂、I期临床试验

摘要号：1028

英文标题：A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease

时间：Monday, December 9, 2024: 4:45 PM

报告人：Ling Qiu

新一代抗CD7通用型CAR-T疗法治疗复发或难治性CD7阳性T-ALL/LBL患者：一项I期临床试验

摘要号：921

英文标题：A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

时间：Monday, December 9, 2024: 3:15 PM

报告人：Yongxian Hu

一项研究者发起的双靶点BCMA/CD19 CAR-T疗法治疗复发/难治性多发性骨髓瘤（包括髓外病变患者）患者的前瞻性Ⅰ/Ⅱ期研究

摘要号：923

英文标题：A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

时间：Monday, December 9, 2024: 3:45 PM

报告人：Hua Jiang

Rovadicitinib治疗对芦可替尼耐药或复发或不耐受的骨髓纤维化患者：一项单臂、多中心、开放标签的Ib期研究

摘要号：484

英文标题：Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study

时间：Sunday, December 8, 2024: 10:15 AM

报告人：Chunkang Chang

新一代JAK2/FLT3抑制剂Flonoltinib Maleate在骨髓纤维化中的首次人体I/IIa期安全性和有效性研究

摘要号：486

英文标题：First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

时间：Sunday, December 8, 2024: 10:45 AM

报告人：Lijuan Chen

塞利尼索联合芦可替尼治疗芦可替尼经治的骨髓纤维化患者的有效性和安全性：一项前瞻性、开放标签、多中心、平行队列、Ⅱ期研究的中期分析

摘要号：1002

英文标题：The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

时间：Monday, December 9, 2024: 5:45 PM

报告人：Minghui Duan

TENT5C作为染色质重塑的靶点SMARCA2通过调节ATP代谢参与套细胞淋巴瘤的BTK抑制剂耐药

摘要号：832

英文标题：TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

时间：Monday, December 9, 2024: 3:30 PM

报告人：Yuting Yan

ST6GALNAC4 通过介导 Bmpr-1B 在 Thr24 位点的唾液酸化促进弥漫大B细胞淋巴瘤进展

摘要号：833

英文标题：ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24

时间：Monday, December 9, 2024: 3:45 PM

报告人：Yu Zhang

利用抗 CD3/CD19 双特异性 T 细胞接合器功能化的工程化外泌体在治疗 B 细胞恶性肿瘤中的靶向递送策略

摘要号：89

英文标题：Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies

时间：Saturday, December 7, 2024: 10:30 AM

报告人：Xiuiu Yang

ERAD活性区分造血干细胞的功能异质性

摘要号：437

英文标题：ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells

时间：Sunday, December 8, 2024: 10:30 AM

报告人：QinLu Peng

SNORD113-114簇通过调控翻译机制维持造血干细胞的自我更新

摘要号：438

英文标题：SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery

时间：Sunday, December 8, 2024: 10:45 AM

报告人：Hui Wang

低剂量芦可替尼用于单倍体相合造血干细胞移植中Gvhd预防的多中心随机对照试验

摘要号：1044

英文标题：A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

时间：Monday, December 9, 2024: 5:45 PM

报告人：Hengwei Wu

TFG-ROS1融合基因是人类髓系白血病的致癌驱动因素

摘要号：38

英文标题：The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia

时间：Saturday, December 7, 2024: 9:45 AM

报告人：Jie Sun

维奈克拉联合地塞米松作为一线治疗t(11;14)轻链淀粉样变性的一项Ⅱ期前瞻性、多中心、单臂研究的初步结果

摘要号：893

英文标题：Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

时间：Monday, December 9, 2024: 3:45 PM

报告人：Kaini Shen

Avapritinib治疗伴KIT突变的复发/难治性或MRD阳性核心结合因子急性髓系白血病患者的前瞻性研究

摘要号：222

英文标题：Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations

时间：Saturday, December 7, 2024: 3:15 PM

报告人：Xueqing Dou

PRC2调控分化阶段特异性自噬基因表达并保护正常红细胞生成

摘要号：538

英文标题：Polycomb Repressive Complex 2 Regulates Differentiation-Stage-Specific Autophagy Gene Expression and Safeguards Normal Erythropoiesis

时间：Sunday, December 8, 2024: 12:45 PM

报告人：Jiazhuo Li

LKB1在幼红细胞脱核中的新作用

摘要号：539

英文标题：A Novel Role of LKB1 in Erythroblast Enucleation

时间：Sunday, December 8, 2024: 1:00 PM

报告人：Yuanlin Xu

线粒体转录-翻译冲突导致剪接因子突变型骨髓增生异常综合征的红细胞生成缺陷和疾病进展

摘要号：345

英文标题：Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes

时间：Saturday, December 7, 2024: 4:30 PM

报告人：Qiaoli Li

β2-肾上腺素受体激动剂特布他林通过HMGB1调节免疫性血小板减少症中的巨噬细胞极化

摘要号：843

英文标题：The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients

时间：Monday, December 9, 2024: 3:15 PM

报告人：Yibo Wu

KRAS基因突变决定KMT2A重排AML患者的预后

摘要号：425

英文标题：β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia

时间：Sunday, December 8, 2024: 10:30 AM

报告人：Qiuyu Guo

分化途径产生功能性偏倚的血小板和对不同生理需求的独特反应

摘要号：426

英文标题：Differentiation Route Generates Functional Biased Platelets and Responses Distinctly to Varying Physiological Demands

时间：Sunday, December 8, 2024: 10:45 AM

报告人：Jingkun Liu

重组人血小板生成素高剂量给药加速异基因造血干细胞移植中的血小板植入：一项前瞻性、剂量优化、对照临床研究

摘要号：266

英文标题：Elevated Dosing of Recombinant Human Thrombopoietin Accelerates Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Dosage-Optimization, Controlled Clinical Study

时间：Saturday, December 7, 2024: 2:15 PM

报告人：Dan Feng

Letermovir用于巨细胞病毒预防时代下的异基因造血干细胞移植后EB病毒再激活与移植后淋巴卒中增殖性疾病

摘要号：268

英文标题：Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

时间：Saturday, December 7, 2024: 2:45 PM

报告人：Jingtao Huang

VA联合改良BuCy预处理序贯Allo-HSCT治疗高危或难治/复发急性淋巴细胞白血病的安全性和有效性：一项前瞻性、单中心、单臂临床试验

摘要号：270

英文标题：Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

时间：Saturday, December 7, 2024: 3:15 PM

报告人：Xiaoqian Chen

在具有成熟循环人红细胞的新型人源化岛小鼠模型中重建巨幼细胞贫血

摘要号：164

英文标题：Reconstruction of Megaloblastic Anemia in a Novel Erythroblastic Island Humanized Mouse Model with Mature Circulating Human Red Blood Cells

时间：Saturday, December 7, 2024: 2:15 PM

报告人：Shuang Liu

细小病毒B19起源于造血干细胞移植后受感染的造血干细胞

摘要号：690

英文标题：Parvovirus B19 Originates from Infected Hematopoietic Stem Cells Following Hematopoietic Stem Cell Transplantation

时间：Sunday, December 8, 2024: 5:45 PM

报告人：Xuying Pei

维奈克拉联合地西他滨与标准强化化疗作为新诊断急性髓系白血病诱导治疗的比较：多中心、随机、2b期试验的更新结果

摘要号：971

英文标题：Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

时间：Monday, December 9, 2024: 5:30 PM

报告人：Jing Lu

大剂量阿糖胞苷联合去甲氧柔红霉素与大剂量阿糖胞苷首次巩固治疗首次完全缓解的急性髓系白血病的比较：一项开放标签、多中心、随机、3期试验

摘要号：972

英文标题：High-Dose Cytarabine with Idarubicin Versus High-Dose Cytarabine within First Consolidation for Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Multicenter, Randomized, Phase 3 Trial

时间：Monday, December 9, 2024: 5:45 PM

报告人：Zinan Feng

CSF-Ctdna 阳性在新诊断弥漫大B细胞淋巴瘤大队列中的临床意义

摘要号：576

英文标题：Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort

时间：Sunday, December 8, 2024: 1:15 PM

报告人：Jinhua Liang

Procr+内皮祖细胞通过Notch信号调节成人造血和微环境稳态

摘要号：562

英文标题：Procr+ Endothelial Progenitor Cells Modulate Adult Hematopoiesis and Microenvironment Homeostasis Via Notch Signaling

时间：Sunday, December 8, 2024: 12:45 PM

报告人：Chang Xu

CAR-T疗法、COVID-19和SLE中细胞因子风暴的单细胞转录组图谱

摘要号：420

英文标题：A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE

时间：Sunday, December 8, 2024: 10:45 AM

报告人：Xia Li

Clec16a 介导的线粒体自噬调节斑马鱼的确定性造血

摘要号：30

英文标题：Clec16a-Mediated Mitophagy Modulates Zebrafish Definitive Hematopoiesis

时间：Saturday, December 7, 2024: 10:45 AM

报告人：Shuyang Cai

通过首个基于凝聚体的基因递送系统高效生成CAR-T细胞

摘要号：150

英文标题：Efficient Generation of CAR-T By the First Coacervate-Based Gene Delivery

时间：Saturday, December 7, 2024: 1:15 PM

报告人：Peipei Zhu

通过PI3Kδ抑制靶向皮肤慢性移植物抗宿主病中的缺氧微环境

摘要号：263

英文标题：Targeting the Hypoxic Microenvironment in Cutaneous Chronic Graft-Versus-Host Disease through PI3Kδ Inhibition

时间：Saturday, December 7, 2024: 3:00 PM

报告人：Yuxi Xu

Faecalibacterium Prausnitzii 对NKT细胞淋巴瘤的进展具有保护作用

摘要号：977

英文标题：Faecalibacterium Prausnitzii Confers a Protective Effect Against the Development of NKTCL

时间：Monday, December 9, 2024: 5:30 PM

报告人：Zhuangzhuang Shi

通过成像质谱流式细胞术和空间转录组揭示EBV+弥漫大B细胞淋巴瘤中免疫微环境的空间结构及其对免疫化疗反应的调控

摘要号：452

英文标题：Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome

时间：Sunday, December 8, 2024: 9:45 AM

报告人：Zhijuan Lin

Hdz-C123A（一种靶向CD123的GSPT1降解抗体偶联物）在体外和体内对急性髓系白血病具有显著疗效

摘要号：156

英文标题：Potent in Vitro and In Vivo Efficacy of Hdz-C123A, a GSPT1 Degrader-Antibody Conjugate Targeting CD123 in Acute Myeloid Leukemia

时间：Saturday, December 7, 2024: 1:15 PM

报告人：Yu Guo

清髓性异基因造血干细胞移植改善晚期NK/T细胞淋巴瘤的预后

摘要号：599

英文标题：Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma

时间：Sunday, December 8, 2024: 1:00 PM

报告人：Zhihui Li

CD38过表达单核细胞在骨髓增殖性肿瘤的纤维化发生中发挥关键作用，并可作为改善纤维化的治疗靶点

摘要号：874

英文标题：CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis

时间：Monday, December 9, 2024: 3:30 PM

报告人：Bing Li

Rbm38通过调控卟啉代谢酶基因亚铁螯合酶（Fech）的RNA选择性剪接、稳定性和翻译调控血红素生物合成

摘要号：12

英文标题：Rbm38 Regulates Heme Biosynthesis Via Fine-Tuning the RNA Alternative Splicing, Stability and Translation of Porphyrin Metabolic Enzyme Gene Ferrochelatase (Fech)

时间：Saturday, December 7, 2024: 10:45 AM

报告人：Yang Mei

利用染色质捕获技术探索由 DNMT3A 突变引起的年龄相关克隆造血中染色质空间结构变化和转录调控的机制

摘要号：192

英文标题：Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology

时间：Saturday, December 7, 2024: 3:15 PM

报告人：Yujun Dai

CD7 CAR-T 细胞疗法在复发或难治性 T 细胞急性淋巴细胞白血病中的应用：一项回顾性研究

摘要号：964

英文标题：CD7 CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Retrospective Study

时间：Monday, December 9, 2024: 5:15 PM

报告人：Jing PAN

单倍体相合外周血干细胞联合骨髓或非血缘脐血作为移植物治疗急性白血病/骨髓增生异常综合征的治疗：一项开放标签、多中心、随机、3期试验

摘要号：696

英文标题：Haploidentical Peripheral Blood Stem Cell Combined with Bone Marrow or Unrelated Cord Blood As Grafts for Acute Leukemia/Myelodysplastic Syndrome: An Open-Label, Multicenter, Randomized, Phase 3 Trial

时间：Sunday, December 8, 2024: 5:45 PM

报告人：Sijian Yu

TNFRSF13B 变异体调控的 TACI 同工型表达失衡促进EB病毒相关淋巴增殖性疾病的进展

摘要号：125

英文标题：Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases

时间：Saturday, December 7, 2024: 1:00 PM

报告人：Xinyue Deng

整合多组学分析鉴定 t(8;21) 急性髓系白血病中预后不良的高风险亚组患者

摘要号：328

英文标题：Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia

时间：Saturday, December 7, 2024: 4:45 PM

报告人：Yu Liu

贝林妥欧单抗加入中国儿童急性B淋巴细胞白血病一线治疗的有效性和安全性

摘要号：312

英文标题：Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia

时间：Saturday, December 7, 2024: 5:15 PM

报告人：Ruidong Zhang

CD33抗体修饰的纳米颗粒包裹的IL-15通过先天免疫途径诱导ISG15促进白血病细胞MHC I表达，从而诱导移植物抗白血病效应而不加重移植物抗宿主病

摘要号：904

英文标题：CD33 Antibody-Modified Nanoparticles Encapsulated IL-15 Induce ISG15 to Promote MHC I Expression in Leukemia Cells Via Innate Immunity Pathway Inducing Graft-Versus-Leukemia without Aggravating Graft-Versus-Host Disease

时间：Monday, December 9, 2024: 3:30 PM

报告人：Ruowen Wei

改良双重CLL1-CD15和CLL1-CD16 Icar-T细胞用于减轻急性髓系白血病治疗中的粒细胞减少症毒性

摘要号：372

英文标题：Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for Mitigating Granulocytopenia Toxicities in the Treatment of Acute Myeloid Leukemia

时间：Saturday, December 7, 2024: 5:15 PM

报告人：Rui Zhang

骨髓单个核细胞的单细胞RNA分析揭示了华氏巨球蛋白血症中T细胞和单核细胞的异常激活，并确定CD35为新的生物标志物和治疗靶点

摘要号：743

英文标题：Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia

时间：Monday, December 9, 2024: 11:30 AM

报告人：Hao Sun

低分子量肝素对蛋白S缺乏症患者妊娠结局的影响：一项前瞻性、随机对照2期临床试验

摘要号：300

英文标题：Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical

时间：Saturday, December 7, 2024: 5:15 PM

报告人：Mengtong Zang

靶向PRMT9通过调节剪接和抑制翻译克服AML中维奈克拉耐药性

摘要号：54

英文标题：Targeting PRMT9 Overcomes Venetoclax Resistance in AML By Modulating Splicing and Inhibiting Translation

时间：Saturday, December 7, 2024: 10:45 AM

报告人：Yang Li